Y-mAbs Therapeutics, Inc.
NASDAQ:YMAB
8.28 (USD) • At close December 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Y-mAbs Therapeutics, Inc. |
Symbool | YMAB |
Munteenheid | USD |
Prijs | 8.28 |
Beurswaarde | 370,853,748 |
Dividendpercentage | 0% |
52-weken bereik | 6.29 - 20.9 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Thomas Gad |
Website | https://www.ymabs.com |
An error occurred while fetching data.
Over Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)